Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Declines By 49.4%

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 36,700 shares, a decline of 49.4% from the February 29th total of 72,500 shares. Based on an average trading volume of 333,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the company’s shares are sold short.

Tenax Therapeutics Price Performance

NASDAQ TENX traded up $0.10 on Thursday, reaching $3.97. The stock had a trading volume of 27,412 shares, compared to its average volume of 354,946. Tenax Therapeutics has a 12-month low of $3.48 and a 12-month high of $61.20. The business’s 50-day moving average price is $6.17 and its 200 day moving average price is $16.92.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Roth Mkm reaffirmed a “buy” rating on shares of Tenax Therapeutics in a research report on Tuesday, February 20th. StockNews.com started coverage on shares of Tenax Therapeutics in a report on Wednesday, January 10th. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Tenax Therapeutics

A hedge fund recently bought a new stake in Tenax Therapeutics stock. Vanguard Group Inc. acquired a new stake in Tenax Therapeutics, Inc. (NASDAQ:TENX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 186,046 shares of the specialty pharmaceutical company’s stock, valued at approximately $51,000. Vanguard Group Inc. owned about 62.02% of Tenax Therapeutics at the end of the most recent quarter. 1.67% of the stock is owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.